Several solid tumors, like sarcomas, prostate, breast, pancreatic, lung, colorectal, and liver carcinomas, show ATP1A1/BCL2L1 levels below the average in the TCGA pan-cancer analysis. This evidence concerns the gene ATP1A1 and hepatocellular carcinoma.